Fennec Pharmaceuticals (FENC) Gains from Investment Securities (2022 - 2025)

Fennec Pharmaceuticals (FENC) has 4 years of Gains from Investment Securities data on file, last reported at $1000.0 in Q2 2025.

• Quarterly Gains from Investment Securities changed N/A year-over-year to $1000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $2000.0 (down 97.53% YoY) and the FY2025 annual result came in at $2000.0, down 97.53% from the prior year.
• Gains from Investment Securities held at $1000.0 in Q2 2025, from $1000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $67000.0 in Q4 2024 to a low of -$4000.0 in Q4 2023.
• A 4-year average of $20000.0 and a median of $11000.0 in 2024 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities sank 106.9% — and 2024, when it jumped 1775.0%.
• Tracing FENC's Gains from Investment Securities over 4 years: stood at $58000.0 in 2022, then sank by 106.9% to -$4000.0 in 2023, then jumped by 1775.0% to $67000.0 in 2024, then sank by 98.51% to $1000.0 in 2025.
• The last three Gains from Investment Securities figures came in at $1000.0 (Q2 2025), $1000.0 (Q1 2025), and $67000.0 (Q4 2024), per Business Quant data.